Oncoceutics, Inc. and its commercial and academic collaborators will be presenting multiple abstracts at the 2019 annual meeting of the American Association for Cancer Research in Atlanta, Georgia, on March 29th to April 3rd. These abstracts will highlight ONC201’s unique mechanism of action, various single agent and combination data, and characterization of other imipridones, including
Advocacy Meeting – Oncoceutics, a clinical-stage drug discovery and development company. Looking forward to hearing about what's fresh and new! And who says SNO meetings aren't fun??? Check out THESE faces! 😉 #SNO2018 #endbraincancer pic.twitter.com/uSOUadi3qN — End Brain Cancer Initiative (@EndBrainCancer) November 17, 2018
Two abstracts will be presented at the 2018 International Symposium on Pediatric Neuro-Oncology (ISPNO), Denver, CO, June 30 – July 3. Additional information on the abstracts can be found below: DIPG-54: “Treatment of a pediatric patient with an H3.3 K27M mutant DIPG with ONC201, a selective DRD2 antagonist”. DIPG-42: “Can we change the landscape
Josh Allen, Senior Vice President of Research and Development at Oncoceutics will share his personal experience as a researcher and will discuss the potential of molecular medicine with respect to cancers like DIPG. Tomorrow’s episode and all previous episodes can be found here. More information about CCTalkRadio can be found here. TogiNet Radio 2.0 is
Business Development